fluorouracil has been researched along with Dysesthesia in 38 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib." | 9.19 | Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014) |
| "To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer." | 8.85 | Capecitabine-based combination therapy for breast cancer: implications for nurses. ( Frye, DK, 2009) |
| " The following key terms were used in the search: hand-foot syndrome, palmar-plantar erythrodysesthesia, capecitabine, Xeloda, colorectal cancer, and metastatic breast cancer." | 8.83 | Management of hand-foot syndrome induced by capecitabine. ( Gressett, SM; Hardwicke, F; Stanford, BL, 2006) |
| "Hand-and-foot syndrome (HFS) is one of the well-known adverse events associated with capecitabine, a prodrug of 5-fluorouracil (5-FU)." | 8.82 | Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. ( Hitti, IF; Narasimhan, P; Narasimhan, S; Rachita, M, 2004) |
| "Comparative trials of capecitabine (Xeloda) versus 5-FU/LV in metastatic colorectal cancer have shown that hand-foot syndrome (HFS) was the only clinical adverse event occurring more frequently with capecitabine." | 8.82 | Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). ( Hoff, P; Lassere, Y, 2004) |
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 7.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| "A case of palmar-plantar erythrodysesthesia syndrome (PPES) observed during a 120-h infusion of 5-fluorouracil (5-FU) is presented." | 7.67 | Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. ( Bellmunt, J; Hidalgo, R; Navarro, M; Solé, LA, 1988) |
| "Some of cancer patients in capecitabine treatment who developed HFS, we recommended to apply henna." | 5.35 | Topical henna for capecitabine induced hand-foot syndrome. ( Guzin, G; Yucel, I, 2008) |
| "Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon)." | 5.34 | [Capecitabine-induced hyperpigmentation]. ( Galán-Gutiérrez, M; Jiménez-Puya, R; Moreno-Giménez, JC; Rodríguez-Bujaldón, AL; Vázquez-Bayo, C, 2007) |
| "Palmar-plantar erythrodysesthesia (PPE) is a distinctive and relatively frequent toxic reaction related to some chemotherapeutic agents." | 5.33 | Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. ( Erkisi, M; Kara, IO; Sahin, B, 2006) |
| "This patient with DPD deficiency manifested a variant of HFS." | 5.33 | Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006) |
| "Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib." | 5.19 | Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014) |
| "Colorectal cancer patients receiving FOLFOX-4 or capecitabine plus oxaliplatin were randomized to (Arm A) calcium gluconate 1g +15% magnesium sulphate 1g diluted in 100 mL of dextrose 5% or (Arm B) placebo." | 5.14 | Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. ( Chay, WY; Choo, SP; Gao, F; Koo, WH; Lo, YL; Ng, HC; Ong, SY; Tan, SH, 2010) |
| "A detailed questionnaire was completed after each chemotherapy cycle for patients with metastatic colorectal cancer enrolled in a phase I trial of oxaliplatin and capecitabine." | 5.11 | Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. ( Fioravanti, S; Grem, JL; Harold, N; Leonard, GD; Quinn, MG; Schuler, B; Thomas, RR; Wright, MA, 2005) |
| "Pegylated liposomal doxorubicin-based combination chemotherapy with capecitabine or gemcitabine was not effective as salvage therapy in advanced hepatocellular carcinoma." | 5.11 | Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. ( Bai, LY; Chen, PM; Poh, SB, 2005) |
| "To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer." | 4.85 | Capecitabine-based combination therapy for breast cancer: implications for nurses. ( Frye, DK, 2009) |
| " The following key terms were used in the search: hand-foot syndrome, palmar-plantar erythrodysesthesia, capecitabine, Xeloda, colorectal cancer, and metastatic breast cancer." | 4.83 | Management of hand-foot syndrome induced by capecitabine. ( Gressett, SM; Hardwicke, F; Stanford, BL, 2006) |
| "Hand-and-foot syndrome (HFS) is one of the well-known adverse events associated with capecitabine, a prodrug of 5-fluorouracil (5-FU)." | 4.82 | Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. ( Hitti, IF; Narasimhan, P; Narasimhan, S; Rachita, M, 2004) |
| "Comparative trials of capecitabine (Xeloda) versus 5-FU/LV in metastatic colorectal cancer have shown that hand-foot syndrome (HFS) was the only clinical adverse event occurring more frequently with capecitabine." | 4.82 | Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). ( Hoff, P; Lassere, Y, 2004) |
| "Palmar-Plantar erythrodyasesthesia syndrome has been reported as a temporary complication of 5-fluorouracil therapy consisting of a debilitating erythema and tenderness of the skin of hands and feet." | 3.69 | Long-term sequelae of Palmar-Plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy. ( Banfield, GK; Crate, ID; Griffiths, CL, 1995) |
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 3.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| "A case of palmar-plantar erythrodysesthesia syndrome (PPES) observed during a 120-h infusion of 5-fluorouracil (5-FU) is presented." | 3.67 | Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. ( Bellmunt, J; Hidalgo, R; Navarro, M; Solé, LA, 1988) |
| "Women with breast carcinoma and four or more involved ipsilateral axillary lymph nodes were randomly assigned to receive an induction course and 2 yr of maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF, 150 patients), CMF plus vincristine and prednisone (CMFVP, 166 patients), or chemoimmunotherapy with CMF plus the methanol extraction residue of BCG (CMF-MER, 85 patients)." | 2.65 | A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. ( Falkson, G; Falkson, HC; Glidewell, OJ; Henry, PH; Holland, JF; Leone, LA; Perloff, M; Tormey, DC; Weinberg, VE; Weiss, RB, 1983) |
| " We also explore different dosing and schedules of capecitabine administration." | 2.46 | Safety of capecitabine: a review. ( Marshall, JL; Mikhail, SE; Sun, JF, 2010) |
| "Palmar-plantar erythrodysesthesia (PPE) or hand-foot syndrome (HFS) is a relatively common side effect of cytotoxic chemotherapy." | 2.44 | Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. ( Harrold, K; How, C; Webster-Gandy, JD, 2007) |
| "Colorectal cancer is one of the most common cancers affecting men and women in the United States." | 2.43 | Advanced colorectal cancer: current treatment and nursing management with economic considerations. ( Fung, A; Viale, PH; Zitella, L, 2005) |
| "Some of cancer patients in capecitabine treatment who developed HFS, we recommended to apply henna." | 1.35 | Topical henna for capecitabine induced hand-foot syndrome. ( Guzin, G; Yucel, I, 2008) |
| "Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon)." | 1.34 | [Capecitabine-induced hyperpigmentation]. ( Galán-Gutiérrez, M; Jiménez-Puya, R; Moreno-Giménez, JC; Rodríguez-Bujaldón, AL; Vázquez-Bayo, C, 2007) |
| "Palmar-plantar erythrodysesthesia (PPE) is a distinctive and relatively frequent toxic reaction related to some chemotherapeutic agents." | 1.33 | Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. ( Erkisi, M; Kara, IO; Sahin, B, 2006) |
| "This patient with DPD deficiency manifested a variant of HFS." | 1.33 | Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006) |
| "The percentage of patients with grade 3 distal paresthesia was lower in Ca/Mg group (7 versus 26%, P = 0." | 1.32 | Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. ( Boisdron-Celle, M; Delva, R; Gamelin, E; Gamelin, L; Guérin-Meyer, V; Ifrah, N; Morel, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.53) | 18.7374 |
| 1990's | 3 (7.89) | 18.2507 |
| 2000's | 19 (50.00) | 29.6817 |
| 2010's | 11 (28.95) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, AK | 1 |
| Khanal, N | 1 |
| Chaulagain, R | 1 |
| Bhujel, N | 1 |
| Singh, RP | 1 |
| Bachet, JB | 1 |
| Lucidarme, O | 1 |
| Levache, CB | 1 |
| Barbier, E | 1 |
| Raoul, JL | 1 |
| Lecomte, T | 1 |
| Desauw, C | 1 |
| Brocard, F | 1 |
| Pernot, S | 1 |
| Breysacher, G | 1 |
| Lagasse, JP | 1 |
| Di Fiore, F | 1 |
| Etienne, PL | 1 |
| Dupuis, OJM | 1 |
| Aleba, A | 1 |
| Lepage, C | 1 |
| Taieb, J | 1 |
| Saura, C | 1 |
| Garcia-Saenz, JA | 1 |
| Xu, B | 1 |
| Harb, W | 1 |
| Moroose, R | 1 |
| Pluard, T | 1 |
| Cortés, J | 1 |
| Kiger, C | 1 |
| Germa, C | 1 |
| Wang, K | 1 |
| Martin, M | 1 |
| Baselga, J | 1 |
| Kim, SB | 1 |
| Beijers, AJ | 1 |
| Mols, F | 1 |
| Tjan-Heijnen, VC | 1 |
| Faber, CG | 1 |
| van de Poll-Franse, LV | 1 |
| Vreugdenhil, G | 1 |
| Amaraneni, A | 1 |
| Seth, A | 1 |
| Itawi, EA | 1 |
| Chandana, SR | 1 |
| Jurado, JM | 1 |
| Pajares, B | 1 |
| Olmos, D | 1 |
| Sevilla, I | 1 |
| Alba, E | 1 |
| Frye, DK | 1 |
| Uña, E | 1 |
| Ferrari, G | 1 |
| Gemignani, F | 1 |
| Macaluso, C | 1 |
| Mikhail, SE | 1 |
| Sun, JF | 1 |
| Marshall, JL | 1 |
| Chay, WY | 1 |
| Tan, SH | 1 |
| Lo, YL | 1 |
| Ong, SY | 1 |
| Ng, HC | 1 |
| Gao, F | 1 |
| Koo, WH | 1 |
| Choo, SP | 1 |
| Amarantidis, K | 1 |
| Xenidis, N | 1 |
| Chelis, L | 1 |
| Chamalidou, E | 1 |
| Dimopoulos, P | 1 |
| Michailidis, P | 1 |
| Tentes, A | 1 |
| Deftereos, S | 1 |
| Karanikas, M | 1 |
| Karayiannakis, A | 1 |
| Kakolyris, S | 1 |
| Fleta-Asín, B | 1 |
| Alcántara-González, J | 1 |
| Alonso-Castro, L | 1 |
| Truchuelo-Díez, M | 1 |
| Jaén-Olasolo, P | 1 |
| Lucchetta, M | 1 |
| Lonardi, S | 1 |
| Bergamo, F | 1 |
| Alberti, P | 1 |
| Velasco, R | 1 |
| Argyriou, AA | 1 |
| Briani, C | 1 |
| Bruna, J | 1 |
| Cazzaniga, M | 1 |
| Cortinovis, D | 1 |
| Cavaletti, G | 1 |
| Kalofonos, HP | 1 |
| Narasimhan, P | 1 |
| Narasimhan, S | 1 |
| Hitti, IF | 1 |
| Rachita, M | 1 |
| Gamelin, L | 1 |
| Boisdron-Celle, M | 1 |
| Delva, R | 1 |
| Guérin-Meyer, V | 1 |
| Ifrah, N | 1 |
| Morel, A | 1 |
| Gamelin, E | 1 |
| Lassere, Y | 1 |
| Hoff, P | 1 |
| Wilkes, GM | 1 |
| Doyle, D | 1 |
| Leonard, GD | 1 |
| Wright, MA | 1 |
| Quinn, MG | 1 |
| Fioravanti, S | 1 |
| Harold, N | 1 |
| Schuler, B | 1 |
| Thomas, RR | 1 |
| Grem, JL | 1 |
| Kara, IO | 1 |
| Sahin, B | 1 |
| Erkisi, M | 1 |
| Viale, PH | 1 |
| Fung, A | 1 |
| Zitella, L | 1 |
| Poh, SB | 1 |
| Bai, LY | 1 |
| Chen, PM | 1 |
| Gressett, SM | 1 |
| Stanford, BL | 1 |
| Hardwicke, F | 1 |
| Saif, MW | 1 |
| Elfiky, A | 1 |
| Diasio, R | 1 |
| Peramiquel, L | 1 |
| Dalmau, J | 1 |
| Puig, L | 1 |
| Roé, E | 1 |
| Fernández-Figueras, MT | 1 |
| Alomar, A | 1 |
| Wang, Y | 1 |
| Xu, RR | 1 |
| Webster-Gandy, JD | 1 |
| How, C | 1 |
| Harrold, K | 1 |
| Shimomatsuya, T | 1 |
| Mitsudou, Y | 1 |
| Nakamura, T | 1 |
| Yonezawa, K | 1 |
| Shiraishi, S | 1 |
| Fujino, M | 1 |
| Maruhashi, K | 1 |
| Vázquez-Bayo, C | 1 |
| Rodríguez-Bujaldón, AL | 1 |
| Jiménez-Puya, R | 1 |
| Galán-Gutiérrez, M | 1 |
| Moreno-Giménez, JC | 1 |
| Yucel, I | 1 |
| Guzin, G | 1 |
| Neijt, JP | 1 |
| ten Bokkel Huinink, WW | 1 |
| van der Burg, ME | 1 |
| van Oosterom, AT | 1 |
| Vriesendorp, R | 1 |
| Kooyman, CD | 1 |
| van Lindert, AC | 1 |
| Hamerlynck, JV | 1 |
| van Lent, M | 1 |
| van Houwelingen, JC | 1 |
| Tormey, DC | 1 |
| Weinberg, VE | 1 |
| Holland, JF | 1 |
| Weiss, RB | 1 |
| Glidewell, OJ | 1 |
| Perloff, M | 1 |
| Falkson, G | 1 |
| Falkson, HC | 1 |
| Henry, PH | 1 |
| Leone, LA | 1 |
| Lokich, JJ | 1 |
| Moore, C | 1 |
| Banfield, GK | 1 |
| Crate, ID | 1 |
| Griffiths, CL | 1 |
| Iurlo, A | 1 |
| Fornier, M | 1 |
| Caldiera, S | 1 |
| Bertoni, F | 1 |
| Foa, P | 1 |
| Haller, DG | 1 |
| Fabian, CJ | 1 |
| Molina, R | 1 |
| Slavik, M | 1 |
| Dahlberg, S | 1 |
| Giri, S | 1 |
| Stephens, R | 1 |
| Bellmunt, J | 1 |
| Navarro, M | 1 |
| Hidalgo, R | 1 |
| Solé, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis[NCT01674309] | Phase 2 | 65 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| A Phase 1/2, Open-Label Study Of Neratinib (HKI-272) In Combination With Capecitabine In Subjects With Solid Tumors And ErbB-2 Positive Metastatic Or Locally Advanced Breast Cancer[NCT00741260] | Phase 1/Phase 2 | 105 participants (Actual) | Interventional | 2008-12-09 | Completed | ||
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of subjects with Complete Response, Partial Response, or Stable Disease at least 24 weeks per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.
| Intervention | percentage of participants (Number) |
|---|---|
| Prior Lapatinib Subjects | 71.4 |
| Lapatinib Naive Subjects P1 | 72.1 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 73.0 |
Duration of response was measured from the time at which response criteria were met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the first date of recurrence or progressive disease (PD) or death per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00741260)
Timeframe: From start date of response to first PD/death, up to three years.
| Intervention | weeks (Median) |
|---|---|
| Prior Lapatinib Subjects | 48.3 |
| Lapatinib Naive Subjects P1 | 46.3 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 46.3 |
MTD reflects the highest dose of capecitabine in combination with neratinib that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.
| Intervention | mg/m^2 (Number) |
|---|---|
| Capecitabine in Combination With Neratinib | 1500 |
MTD reflects the highest dose of neratinib plus capeciteabine that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.
| Intervention | mg (Number) |
|---|---|
| Neratinib in Combination With Capecitabine | 240 |
Number of participants reporting Adverse Events Causing Dose Limiting Toxicities (DLT). (NCT00741260)
Timeframe: From first dose date to day 21
| Intervention | Participants (Count of Participants) |
|---|---|
| N160 + C1500 | 0 |
| N160 + C2000 | 2 |
| N200 + C2000 | 2 |
| N240 + C1500 | 0 |
| N240 + C2000 | 2 |
| N + C MTD - No Prior Lap | 0 |
| N + C MTD - Prior Lap | 0 |
Number of Subjects with Complete or Partial Response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.
| Intervention | percentage of participants (Number) |
|---|---|
| Prior Lapatinib Subjects | 57.1 |
| Lapatinib Naive Subjects P1 | 63.9 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 63.5 |
12 reviews available for fluorouracil and Dysesthesia
| Article | Year |
|---|---|
How effective is 5-Fluorouracil as an adjuvant in the management of odontogenic keratocyst? A systematic review and meta-analysis.
Topics: Adjuvants, Immunologic; Fluorouracil; Humans; Odontogenic Cysts; Odontogenic Tumors; Paresthesia | 2022 |
Oxaliplatin-induced Lhermitte sign. A case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2014 |
Capecitabine-based combination therapy for breast cancer: implications for nurses.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marr | 2009 |
Safety of capecitabine: a review.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2010 |
Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Black People; Capecitabine; Deoxycytidine; Erythema; F | 2004 |
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
Topics: Activities of Daily Living; Algorithms; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitab | 2004 |
Palmar-plantar erythrodysesthesia.
Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Doxorubicin; Drug Eruptions; Erythema; Fem | 2005 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt | 2005 |
Management of hand-foot syndrome induced by capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Foot Injuries; Hand Inju | 2006 |
[Progress of study on prevention and treatment of xeloda induced hand-foot syndrome by measures of Chinese and Western medicine].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Therapy; Drugs, Chinese Herbal; F | 2007 |
Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
Topics: Activities of Daily Living; Antineoplastic Agents; Cancer Care Facilities; Cryotherapy; Cytarabine; | 2007 |
Safety of oxaliplatin in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 2000 |
8 trials available for fluorouracil and Dysesthesia
| Article | Year |
|---|---|
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2018 |
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot | 2014 |
Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Gluconate; Capecita | 2010 |
Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials a | 2005 |
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1984 |
A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; BCG Vaccine; Breast Neoplasms; | 1983 |
18 other studies available for fluorouracil and Dysesthesia
| Article | Year |
|---|---|
Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 2015 |
'Out of blue' Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fl | 2008 |
Atypical presentation of acute neurotoxicity secondary to oxaliplatin.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Chemotherapy-associated peripheral sensory neuropathy assessed using in vivo corneal confocal microscopy.
Topics: Aged; Capecitabine; Carcinoma; Colorectal Neoplasms; Cornea; Deoxycytidine; Fluorouracil; Humans; Ma | 2010 |
Genital erythrodysesthesia as a severe manifestation of capecitabine therapy: a report of 3 cases.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Erythema; Flu | 2011 |
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2012 |
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calcium; Calcium Glucon | 2004 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecita | 2006 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecita | 2006 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecita | 2006 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecita | 2006 |
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deficiency Diseases; Deoxycyt | 2006 |
Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidin | 2006 |
[A case of severe hand-foot syndrome caused by capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration | 2007 |
[Capecitabine-induced hyperpigmentation].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Female; F | 2007 |
Topical henna for capecitabine induced hand-foot syndrome.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine | 2008 |
Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; | 1984 |
Long-term sequelae of Palmar-Plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy.
Topics: Erythema; Fluorouracil; Humans; Male; Middle Aged; Paresthesia | 1995 |
Palmar-plantar erythrodysaesthesia syndrome due to 5-fluorouracil therapy--an underestimated toxic event?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Erythema; Female; F | 1997 |
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.
Topics: Colonic Neoplasms; Edema; Erythema; Fluorouracil; Follow-Up Studies; Foot Dermatoses; Hand Dermatose | 1990 |
Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil.
Topics: Carcinoma, Squamous Cell; Erythema; Fluorouracil; Foot; Hand; Humans; Male; Middle Aged; Paresthesia | 1988 |